CoreCap Advisors’s Titan Pharmaceuticals TTNP Stock Holding History

CoreCap Advisors’s Portfolio TTNP Stock Details TTNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$65	Hold	88	–	–	﹤0.01%	3106
2026 Q1	$123	Hold	88	–	–	﹤0.01%	2818
2025 Q4	$147	Hold	88	–	–	﹤0.01%	2843
2025 Q3	$422	Hold	88	–	–	﹤0.01%	2593
2025 Q2	$370	Hold	88	–	–	﹤0.01%	2552
2025 Q1	$311	Buy	+88	New	+$317	﹤0.01%	2807

Other funds holding TTNP

DJSG

D.J. St. Germain Springfield, Massachusetts $2.78B AUM 23.87% 1-Year Est. Return

FFA

Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

CoreCap Advisors's TTNP Position: Q2 2026 in Review

CoreCap Advisors held its Titan Pharmaceuticals (TTNP) position steady in Q2 2026 at 88 shares worth $65. The position accounts for ﹤0.01% of the portfolio, ranked #3106.

CoreCap Advisors first reported a position in TTNP in Q1 2025 and has held it in 6 quarters since. The position peaked at $422 in Q3 2025. 3 funds tracked by Wall St. Rank hold TTNP as of Q2 2026.

CoreCap Advisors held 88 shares of Titan Pharmaceuticals worth $65 as of Q2 2026.
CoreCap Advisors left its Titan Pharmaceuticals share count unchanged in Q2 2026.
Titan Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #3106 holding.
CoreCap Advisors first reported a position in Titan Pharmaceuticals in Q1 2025 and has held it in 6 quarters since.
CoreCap Advisors's Titan Pharmaceuticals position peaked at $422 in Q3 2025.
3 funds tracked by Wall St. Rank held Titan Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.